The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

A woman felt like she was being "ripped open by a knife" after suffering extreme reaction to single weight loss jab Mounjaro.

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Experts concerned over promotional strategies of Eli Lilly for tirzepatide: Shardul Nautiyal, Mumbai Friday, April 11, 2025, 08:00 Hrs [IST] As Mounjaro (tirzepatide), the blockbu ...

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Amy Schumer shared she quit Wegovy due to side effects like nausea but was "having a really good experience" with Mounjaro, ...